FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252016915> ?p ?o ?g. }

• W4252016915 abstract "Abstract Background Several SARS-CoV-2 vaccines have shown clinical efficacy against Covid-19 infection but there remains uncertainty about the immune responses elicited by different regimens. This is a particularly important question for older people who are at increased clinical risk following infection and in whom immune senescence may limit vaccine responses. The BNT162b2 mRNA and ChAdOx1 adenovirus vaccines were the first two vaccines deployed in the UK programme using an 8-12 week ‘extended interval’. Objectives We undertook analysis of the spike-specific antibody and cellular immune response in 131 participants aged 80+ years after the second dose of ‘extended interval’ dual vaccination with either BNT162b2 mRNA (n=54) or ChAdOx1 (n=77) adenovirus vaccine. Blood samples were taken 2-3 weeks after second vaccine and were paired with samples taken at 5-weeks after first vaccine which have been reported previously. Antibody responses were measured using the Elecsys® electrochemiluminescence immunoassay assay and cellular responses were assessed by IFN-g ELISpot. Results Antibody responses against spike protein became detectable in all donors following dual vaccination with either vaccine. 4 donors had evidence of previous natural infection which is known to boost vaccine responses. Within the 53 infection-naïve donors the median antibody titre was 4030 U/ml (IQR 1892-8530) following BNT162b2 dual vaccination and 1405 (IQR 469.5- 2543) in the 74 patients after the ChAdOx1 vaccine (p=<0.0001). Spike-specific T cell responses were observed in 30% and 49% of mRNA and ChAdOx1 recipients respectively and median responses were 1.4-times higher in ChAdOx1 vaccinees at 14 vs 20 spots/million respectively (p=0.022). Conclusion Dual vaccination with BNT162b2 or ChAdOx1 induces strong humoral immunity in older people following an extended interval protocol. Antibody responses are 2.9-times higher following the mRNA regimen whilst cellular responses are 1.7-times higher with the adenovirus-based vaccine. Differential patterns of immunogenicity are therefore elicited from the two vaccine platforms. It will be of interest to assess the relative stability of immune responses after these homologous vaccine regimens in order to assess the potential need for vaccine boosting. Furthermore, these findings indicate that heterologous vaccine platforms may offer the opportunity to further optimize vaccine responses." @default.
• W4252016915 created "2022-05-12" @default.
• W4252016915 creator A5003190034 @default.
• W4252016915 creator A5008173791 @default.
• W4252016915 creator A5029062886 @default.
• W4252016915 creator A5041521389 @default.
• W4252016915 creator A5045712115 @default.
• W4252016915 creator A5068922045 @default.
• W4252016915 creator A5074402688 @default.
• W4252016915 creator A5079855257 @default.
• W4252016915 creator A5085665804 @default.
• W4252016915 date "2021-07-20" @default.
• W4252016915 modified "2023-09-28" @default.
• W4252016915 title "Differential Immunogenicity of BNT162b2 or ChAdOx1 Vaccines After Extended-Interval Homologous Dual Vaccination in Older People" @default.
• W4252016915 doi "https://doi.org/10.21203/rs.3.rs-727799/v1" @default.
• W4252016915 hasPublicationYear "2021" @default.
• W4252016915 type Work @default.
• W4252016915 citedByCount "0" @default.
• W4252016915 crossrefType "posted-content" @default.
• W4252016915 hasAuthorship W4252016915A5003190034 @default.
• W4252016915 hasAuthorship W4252016915A5008173791 @default.
• W4252016915 hasAuthorship W4252016915A5029062886 @default.
• W4252016915 hasAuthorship W4252016915A5041521389 @default.
• W4252016915 hasAuthorship W4252016915A5045712115 @default.
• W4252016915 hasAuthorship W4252016915A5068922045 @default.
• W4252016915 hasAuthorship W4252016915A5074402688 @default.
• W4252016915 hasAuthorship W4252016915A5079855257 @default.
• W4252016915 hasAuthorship W4252016915A5085665804 @default.
• W4252016915 hasBestOaLocation W42520169151 @default.
• W4252016915 hasConcept C159654299 @default.
• W4252016915 hasConcept C203014093 @default.
• W4252016915 hasConcept C22070199 @default.
• W4252016915 hasConcept C2776090121 @default.
• W4252016915 hasConcept C2779053233 @default.
• W4252016915 hasConcept C2780868878 @default.
• W4252016915 hasConcept C71924100 @default.
• W4252016915 hasConcept C8891405 @default.
• W4252016915 hasConceptScore W4252016915C159654299 @default.
• W4252016915 hasConceptScore W4252016915C203014093 @default.
• W4252016915 hasConceptScore W4252016915C22070199 @default.
• W4252016915 hasConceptScore W4252016915C2776090121 @default.
• W4252016915 hasConceptScore W4252016915C2779053233 @default.
• W4252016915 hasConceptScore W4252016915C2780868878 @default.
• W4252016915 hasConceptScore W4252016915C71924100 @default.
• W4252016915 hasConceptScore W4252016915C8891405 @default.
• W4252016915 hasLocation W42520169151 @default.
• W4252016915 hasLocation W42520169152 @default.
• W4252016915 hasLocation W42520169153 @default.
• W4252016915 hasLocation W42520169154 @default.
• W4252016915 hasOpenAccess W4252016915 @default.
• W4252016915 hasPrimaryLocation W42520169151 @default.
• W4252016915 hasRelatedWork W1970289093 @default.
• W4252016915 hasRelatedWork W2010003444 @default.
• W4252016915 hasRelatedWork W2029074520 @default.
• W4252016915 hasRelatedWork W2059844374 @default.
• W4252016915 hasRelatedWork W2166919567 @default.
• W4252016915 hasRelatedWork W2392253556 @default.
• W4252016915 hasRelatedWork W2411114470 @default.
• W4252016915 hasRelatedWork W3183308739 @default.
• W4252016915 hasRelatedWork W4221063257 @default.
• W4252016915 hasRelatedWork W4286856427 @default.
• W4252016915 isParatext "false" @default.
• W4252016915 isRetracted "false" @default.
• W4252016915 workType "article" @default.